Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Palatin's (PTN) To Report Q4 Earnings: What's In The Cards?

By Zacks Investment ResearchStock MarketsAug 15, 2019 10:42PM ET
www.investing.com/analysis/palatins-ptn-to-report-q4-earnings-whats-in-the-cards-200455877
Palatin's (PTN) To Report Q4 Earnings: What's In The Cards?
By Zacks Investment Research   |  Aug 15, 2019 10:42PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Palatin Technologies, Inc. (NYSE:PTN) will focus on the commercialization of Vyleesi in the fourth quarter of fiscal 2019.

Shares of the company have rallied 23.9% year to date against the industry’s decline of 3.0%.

In the last reported quarter, the company witnessed a negative earnings surprise of 50.00%. Moreover, Palatinsurpassed earnings estimates in one of the trailing four quarters, the average positive surprise being 37.50%.

Let’s see how things are shaping up prior to the upcoming results.

Factors Likely to Impact Q4 Results

In June 2019, the FDA granted marketing approval to AMAG Pharmaceuticals, Inc.'s (NASDAQ:AMAG) new drug application (NDA) for Vyleesi (bremelanotide injection), a melanocortin receptor agonist developed by Palatin, indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The FDA's approval of the NDA triggers a $60-million milestone payment to Palatin under its North American license agreement with AMAG. In the second quarter, we expect Palatin to provide commercialization updates on the drug.

The company should also provide updates on its pipeline candidates during the quarter.

Palatin’s new product development activities primarily focus on melanocortin receptor 1 (“MC1r”) agonists, with potential to treat a number of inflammatory and autoimmune diseases such as dry eye disease (also known as keratoconjunctivitis sicca), uveitis, diabetic retinopathy and inflammatory bowel disease.

The company has also designed and is developing potential NPR candidates that are selective for one or more different natriuretic peptide receptors (NPR), including natriuretic peptide receptor-A (“NPR-A”), natriuretic peptide receptor B (“NPR-B”) and natriuretic peptide receptor C (“NPR-C”).

PL-3994 is an NPR-A agonist, which has completed phase I clinical safety studies. It has potential in the treatment of several cardiovascular diseases, including genetic and orphan diseases resulting from a deficiency of endogenous active NPR-A. The company has ongoing academic collaborations with several institutions for PL-3994.

PL-5028, a dual NPR-A and NPR-C agonist, is in preclinical development for cardiovascular diseases to reduce cardiac hypertrophy and fibrosis. The company has ongoing academic collaborations with several institutions for PL-5028 and seeks to enter a development partnership for the same by the end of calendar year 2019.

What Does the Zacks Model Unveil?

Our proven model does not conclusively show an earnings beat for Palatin in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.

Earnings ESP: Palatin has an Earnings ESP of 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 2 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently has a Zacks Rank #2, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.

Note that Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement are best avoided.

Stocks That Warrant a Look

Here are some drug/biotech stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) has an Earnings ESP of +0.49% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Celgene Corporation (NASDAQ:CELG) has an Earnings ESP of +0.27% and a Zacks Rank #3.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>



AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report

Celgene Corporation (CELG): Free Stock Analysis Report

ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report

Palatin Technologies, Inc. (PTN): Free Stock Analysis Report

Original post

Zacks Investment Research
Palatin's (PTN) To Report Q4 Earnings: What's In The Cards?
 

Related Articles

Palatin's (PTN) To Report Q4 Earnings: What's In The Cards?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email